|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001175,
umls-concept:C0019682,
umls-concept:C0019691,
umls-concept:C0019693,
umls-concept:C0019699,
umls-concept:C0030946,
umls-concept:C0035647,
umls-concept:C0036043,
umls-concept:C0205251,
umls-concept:C0282472,
umls-concept:C0328767,
umls-concept:C0332283,
umls-concept:C0332307,
umls-concept:C0597551,
umls-concept:C0675907,
umls-concept:C1032657,
umls-concept:C1050646,
umls-concept:C1257890,
umls-concept:C1521801,
umls-concept:C1548795,
umls-concept:C1708335
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1999-8-6
|
|
pubmed:abstractText |
A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogenicity. Both antigens were well tolerated. ALVAC-HIV (vCP205) induced low levels of neutralizing antibodies against HIV-1 MN in 33% of the volunteers. None of them had detectable neutralizing antibodies against a nonsyncytium-inducing HIV-1 clade B primary isolate (Bx08). After the fourth injection of vCP205, CTL activity was detected in 33% of the volunteers and was directed against Env, Gag, and Pol. This activity was mediated by both CD4+ and CD8+ lymphocytes. On the other hand, the CLTB-36 peptide was poorly immunogenic and induced no neutralizing antibodies or CTLs. Although the ALVAC-HIV (vCP205) and CLTB-36 prime-boost regimen was not optimal, further studies with ALVAC-HIV (vCP205) are warranted because of its clear induction of a cellular immune response and utility as a priming agent for other subunit antigens such as envelope glycoproteins, pseudoparticles, or new peptides.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0889-2229
|
|
pubmed:author |
pubmed-author:AutranBB,
pubmed-author:BlondeauCC,
pubmed-author:ChongPP,
pubmed-author:El HabibRR,
pubmed-author:ExclerJ LJL,
pubmed-author:FinkielsztejnLL,
pubmed-author:GluckmanJ CJC,
pubmed-author:HeshmatiFF,
pubmed-author:KleinMM,
pubmed-author:MatthewsT JTJ,
pubmed-author:MeignierBB,
pubmed-author:MilcampsBB,
pubmed-author:OrelG LGL,
pubmed-author:PlotkinSS,
pubmed-author:RauxMM,
pubmed-author:Salmon-CéronDD,
pubmed-author:SicardDD,
pubmed-author:TartagliaJJ,
pubmed-author:ValentinCC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
633-45
|
|
pubmed:dateRevised |
2006-4-21
|
|
pubmed:meshHeading |
pubmed-meshheading:10331442-AIDS Vaccines,
pubmed-meshheading:10331442-Adult,
pubmed-meshheading:10331442-Amino Acid Sequence,
pubmed-meshheading:10331442-Avipoxvirus,
pubmed-meshheading:10331442-Female,
pubmed-meshheading:10331442-Genetic Vectors,
pubmed-meshheading:10331442-HIV Antibodies,
pubmed-meshheading:10331442-HIV Core Protein p24,
pubmed-meshheading:10331442-HIV Envelope Protein gp120,
pubmed-meshheading:10331442-HIV-1,
pubmed-meshheading:10331442-Humans,
pubmed-meshheading:10331442-Immunization, Secondary,
pubmed-meshheading:10331442-Immunization Schedule,
pubmed-meshheading:10331442-Lymphocyte Activation,
pubmed-meshheading:10331442-Male,
pubmed-meshheading:10331442-Middle Aged,
pubmed-meshheading:10331442-Molecular Sequence Data,
pubmed-meshheading:10331442-Peptides,
pubmed-meshheading:10331442-T-Lymphocytes,
pubmed-meshheading:10331442-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:10331442-Vaccines, Synthetic
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
|
|
pubmed:affiliation |
CHU Cochin AP HP, Universite Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
